an efficacy and safety study of genolar® and xolar® in the persistent atopic bronchial asthma

Conditions: Bronchial Asthma

Summary: this is a randomized, double-blind, comparative, parallel-group study of the efficacy and safety of genolar® and xolair® in the treatment of persistent atopic bronchial asthma of moderate and severe course, whose symptoms are insufficiently controlled by the 4-step treatment gina (2017)

there is an increasing incidence of bronchial asthma (ba) and other allergic diseases around the world. bronchial asthma suffers from 4 to 10% of the world population, in russian federation, the incidence of ba across the adult population ranges from 2.2 to 5-7%, in the child population is about 10%. severe ba is associated not only with frequent hospitalizations and increased mortality but also with high treatment costs. as to it, there is a hot button issue of developing new drugs for treating patients not to be achieved effectively with standard therapy. considering the leading pathogenesis role of ige-mediated allergy, the use of drugs to block ige makes it possible to control the disease at the earliest allergic reaction phase of the development. it was shown that the ige elimination from the mast cells and basophils surface reduced the severity of acute allergic reactions, reduced the allergen-induced late phase of the immune response and infiltration with inflammatory cells. these anti-ige antibodies effects have been shown in various studies. genolar® (omalizumab) (jsc "generium", the russian federation) is a humanized recombinant monoclonal antibody selectively binding to immunoglobulin (ige) and is a biosimilar of xolar® ("novartis pharma ag", switzerland). this iii phase study is aimed to compare the effectiveness, safety and immunogenicity of genolar® (jsc "generium", russia) and xolair® to register of the drug genolar® (jsc "generium", the russian federation), a lyophilizate for subcutaneous administration, in the russian federation. the study included patients (n = 192) aged 18 to 75 years with moderate to severe persistent atopic bronchial asthma. the diagnosis was documented for ≥1 year. the symptoms of the disease were insufficiently controlled by therapy corresponding to the 4th stage of treatment (gina, 2017) during ≥2 months before screening. with block randomization, the patients were divided into two groups in a 2: 1 ratio: in group 1 - 127 patients received treatment with genolar® for 52 weeks ± 3 days, in group 2 - 64 patients received treatment with xolair® for 26 weeks ± 3 days. the study consisted of a screening period, an induction period for basic treatment standardizing with the using inhaled budesonide + formoterol, a comparative period of treatment with the studied drugs (genolar® vs. xolair®) for 26 weeks ± 3 days, and an additional period of continuing treatment with genolar® for 26 ± 1 week for its long-term immunogenicity study.

Eligibility criteria:
inclusion criteria: 1. men and women of the ages between 18 and 75 at the time of the informed consent form signature. 2. a documented diagnosis of bronchial asthma for ≥1 year before the screening; 3. 4th stage of asthma treatment according to gina (2017) ≥2 months before the screening; 4. the fev1 value measured ≥4 hours after the last inhalation of short-acting β2-agonists or ≥12 hours after the last inhalation of long-acting β2-agonists is in the range of ≥40% and ≤80% of the proper value; 5. a positive test result for the obstruction reversibility, which is defined as an increase in fev1 \> 12% and \> 200 ml from the baseline value, which is measured if inhaled short-acting β2-agonists are withdrawn for ≥4 hours or long-acting β2-agonists ≥12 hours, after 10-15 minutes after inhalation 200-400 mcg salbutamol or equivalent. or 6. daily pef variability for 2 weeks before randomization is \>10%, which is defined as the pef amplitude between the maximum and minimum values during the day, expressed as an average daily pef percentage and averaged over 2 weeks: (\[maximum per day value - minimum per day value\] / average of the maximum and minimum values per day), averaged over 2 weeks and multiplied by 100%; 7. insufficiently controlled asthma at the screening despite the correct inhaler use and good adherence to the 4th stage of bronchial asthma treatment (gina 2017); and the lack of asthma control reasons are not in concomitant diseases, for example, allergic rhinitis. insufficiently controlled asthma is defined as ≥1.5 points on the acq-5 asthma control questionnaire (asthma control questionnaire); 8. atopy for common environmental allergens confirmed at the screening, or documented atopy for common environmental allergens in history. exclusion criteria: 1. the initial concentration of total ige and body weight do not correspond to the range in the dosing table for omalizumab dose-ranging. 2. asthma resistant to glucocorticosteroids (inhaled, oral or parenteral). 3. current smokers, smoker's index (pack / years) \>10. smoker's index (pack / years) = number of cigarettes smoked per day × smoking experience (years) / 20. 4. asthma exacerbation during the 4 weeks before randomization. 5. asthma treatment regimen changes during the introductory trial period during which the basic therapeutic drug symbicort turbuhaler was admitted, until the first injection of study drugs. 6. skipped the basic inhalations with symbicort® turbuhaler® during the introductory period of the trial more than 20%. 7. patients with severe medical conditions that in the view of the investigator prohibits participation in the study. 8. pregnant or nursing (lactating) women. 9. monoclonal antibodies administration within 1 year before taking omalizumab. 10. hypersensitivity to any of the used study drug, to their components, history of an undesirable drug reaction. 11. a history of autoimmune disease.

Keywords: omalizumab humanized monoclonal antibodies safety bronchial asthma equivalence biosimilar anti-allergic agents anti-asthmatic agents respiratory system agents hypersensitivity immune system diseases urticaria immunogenicity